While our study suggested that blocking DDX5 protein expression may be beneficial in the treatment of HCC patients, the therapeutic strategy targeting DDX5 in patients with HCC needs to be individualized, because the functional role of this protein in HCC pathogenesis was unique and varied depending on the patient being treated. This evidence concerns the gene DDX5 and hepatocellular carcinoma.